Health care providers should not use products intended as sterile made by North American Custom Laboratories LLC, FarmaKeio Superior Custom Compounding in Richardson, Texas, because the products may not be sterile, the Food and Drug Administration warned yesterday. Administering a non-sterile drug intended as sterile may result in life-threatening consequences, including infections and sepsis. FDA was not aware of any illness associated with using the drugs. The agency recommends providers and patients report unexpected side effects or quality problems associated with the drugs to its MedWatch program.

Related News Articles

Headline
In this “Safety Speaks” conversation, CommonSpirit Health's Beth Miller, system director, patient safety-performance improvement, and Austin Peterson, system…
Headline
The Food and Drug Administration Feb. 23 withdrew approval of Pepaxto (melphalan flufenamide), a drug once used with dexamethasone to treat certain U.S.…
Headline
AHA today submitted comments on how the Agency for Healthcare Research and Quality can best support the field in advancing patient safety through an…
Headline
Abbott has recalled certain lots of its Dragonfly OpStar imaging catheter because a marker band may separate from the catheter and remain in the patient after…
Headline
AHA today urged the Federal Trade Commission to scrutinize commercial health plans that steer patients to third-party specialty pharmacies in which they have a…
Headline
The Food and Drug Administration last week extended to 24 months the shelf life for certain lots of refrigerated bamlanivimab. The combination monoclonal…